Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results Call Set for August 10
Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results... -- VENLO, The Netherlands, Aug. 3 /PRNewswire-FirstCall/ --
Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results Call Set for August 10
VENLO, The Netherlands, Aug. 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: [ QGEN ]) today announced the Webcast of its second quarter 2010 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 10, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
What: | Webcast of QIAGEN's second quarter 2010 financial results call | |
When: | 9:30 a.m. EDT on August 10 | |
Where: | The Webcast is accessible at [ www.qiagen.com/goto/ConferenceCall ] | |
How: | Log on to the Web at the address above | |
The corresponding presentation slides will be available for download in the investor relations section of QIAGEN's Web site at [ www.qiagen.com/goto/ConferenceCall ]. | ||
Contact: | Andreas Marathovouniotis, Russo Partners, (212) 845-4235 | |
QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.
QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at [ www.qiagen.com ].
(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from [ http://www.real.com/products/player/index.html ], or The Windows Media Player, downloadable free from [ www.microsoft.com ] and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to [ prnwebcast@multivu.com ].)
SOURCE QIAGEN N.V.
[ Back to top ]RELATED LINKS
[ http://www.qiagen.com ]
Other News Releases in Biotechnology
[ Access Pharmaceuticals Furthers Clinical Development Program of Thiarabine in Patients with Hematologic Malignancies ]
[ Volcano Corporation Presentation at Canaccord Genuity Growth Conference to be Webcast ]
[ Boston Scientific Begins Clinical Trial Enrollment for New Coronary Stent with Bioabsorbable Polymer and Everolimus Drug Coating ]
Journalists and Bloggers
Visit [ PR Newswire for Journalists ] for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on [ The Digital Center ].